Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023

Author:

Fontán-Vela Mario12ORCID,Kissling Esther3,Nicolay Nathalie4,Braeye Toon5,Van Evercooren Izaak5,Holm Hansen Christian6,Emborg Hanne-Dorthe6,Fabiani Massimo7,Mateo-Urdiales Alberto7,AlKerwi Ala'a8,Schmitz Susanne8,Castilla Jesús910,Martínez-Baz Iván910,de Gier Brechje11,Hahné Susan11,Meijerink Hinta12,Starrfelt Jostein12,Nunes Baltazar13,Caetano Constantino13,Derrough Tarik4,Nardone Anthony3,Monge Susana142,

Affiliation:

1. Public Health and Epidemiology research group, School of Medicine and Health Sciences, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain

2. National Centre of Epidemiology, Carlos III National Health Institute (ISCIII), Madrid, Spain

3. Epiconcept, Paris, France

4. Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

5. Sciensano, Elsene, Belgium

6. Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut (SSI), Copenhagen, Denmark

7. Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy

8. Ministry of Health, Directorate of Health, Service epidemiology and statistics, Luxembourg

9. CIBER Epidemiología y Salud Pública (CIBERESP), Spain

10. Instituto de Salud Pública de Navarra – IdiSNA, Pamplona, Spain

11. Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands

12. Norwegian Institute of Public Health (NIPH), Oslo, Norway

13. Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Departamento de Epidemiologia, Lisboa, Portugal

14. CIBER on Infectious Diseases (CIBERINFEC), Madrid, Spain

Abstract

To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021–July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65–79-year-olds.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference18 articles.

1. Epiconcept. Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza. Paris: Epiconcept. [Accessed 6 Oct 2023]. Available from: https://www.epiconcept.fr/en/epidemio-project/vaccine-effectiveness-burden-and-impact-studies-vebis-of-covid-19-and-influenza

2. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.;Sentís;Euro Surveill,2022

3. Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.;Kislaya;Influenza Other Respir Viruses,2023

4. European Centre for Disease Prevention and Control (ECDC). Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries. Stockholm: ECDC; 30 Nov 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/interim-analysis-covid-19-vaccine-effectiveness-against-hospitalisation-and-death

5. European Centre for Disease Prevention and Control (ECDC). Pilot protocol for a COVID-19 vaccine effectiveness study using health data registries: version 1.0. Stockholm: ECDC; 19 Sep 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-pilot-protocol-vaccine-effectiveness-study-using-health-data-registries

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3